Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Many anemic chronic kidney disease (CKD) patients are refractory to erythropoietin (EPO) effects due to inflammation, deranged iron utilization, and generation of EPO antibodies. This work assessed the effect of desidustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase (PHD), on...

Descripción completa

Detalles Bibliográficos
Autores principales: Joharapurkar, Amit A., Patel, Vishal J., Kshirsagar, Samadhan G., Patel, Maulik S., Savsani, Hardikkumar H., Kajavadara, Chetan, Valani, Darshan, Jain, Mukul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096675/
https://www.ncbi.nlm.nih.gov/pubmed/35570856
http://dx.doi.org/10.1016/j.crphar.2022.100102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096675/
https://www.ncbi.nlm.nih.gov/pubmed/35570856
http://dx.doi.org/10.1016/j.crphar.2022.100102

Ejemplares similares